GleamWall
中文EN

SCLX Scilex Holding Co

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1820190 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-28.5%
TTM net income YoY-473.7%
TTM EPS YoY-2,120.1%
Revenue 3-yr CAGR-12.0%
Net income 3-yr CAGR—

Margins

Gross margin161.1%
Operating margin-1,136.4%
Net margin-1,469.8%
FCF margin—
EBITDA margin-1,119.8%

Returns

ROE—
ROA-275.4%
ROIC (approx.)—
Asset turnover0.19x

Leverage & solvency

Liabilities / assets222.5%
Debt / equity—
Current ratio0.07x
Interest coverage-22.20x

Cash quality & payout

Operating cash flow / net income0.04x
Accruals ratio-265.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue$7.64M$8.61M$4.79M$10.56M$9.90M$5.00M$14.90M$14.44M
Cost of revenue$3.68M$4.45M$2.61M$3.33M$3.27M$1.38M$4.69M$3.77M
Gross profit$15.80M$25.70M$2.18M$7.23M$39.50M$17.70M$10.21M$10.67M
R&D expense$3.34M$3.21M$8.17M$3.90M$6.19M$2.46M$2.18M$2.35M
SG&A expense$27.96M$31.03M$30.16M$188.82M$19.84M$28.06M$35.41M$29.73M
Operating income-$29.42M-$32.17M-$111.09M-$186.51M-$20.51M-$27.90M-$28.38M-$19.92M
Interest expense$6.10M$3.78M$3.50M$2.80M$2.68M$2.48M$285,000$576,000
Pretax income-$114.98M-$45.65M-$46.10M-$257.82M-$44.03M-$26.08M-$6.46M-$4.39M
Income tax$7,000—$6,000$1,000$19,000—-$1,000$0
Net income-$114.99M-$45.65M-$46.10M-$257.82M-$44.05M-$26.08M-$6.46M-$4.39M
EBITDA-$28.62M-$29.30M-$109.50M-$186.51M-$20.50M-$26.89M-$27.37M-$19.91M
EPS (basic)-16.65-6.28—-22.17-7.42-2.26—-0.58
EPS (diluted)-16.65-6.28—-22.17-7.42-2.26—-0.58
Weighted avg. shares (diluted)6.89M6.89M—11,60411.60M11.56M—7,557
Banking
Provision for credit losses$73,000$800,000—$0$0$0——
Balance sheet
Cash & equivalents$566,000$3.35M$4.96M$878,000$4.10M$5.80M$3.27M$8.12M
Receivables$6.44M$10.65M$15.24M$11.94M$16.77M$10.62M$26.44M$31.58M
Inventory$4.17M$4.53M$4.79M$1.08M$2.52M$3.02M$2.44M$2.40M
Current assets$36.23M$41.97M$38.36M$16.49M$33.67M$28.70M$41.55M$39.85M
PP&E, net$12.77M$13.38M$13.60M$703,000$705,000$707,000$708,000$711,000
Goodwill$13.48M$13.48M$13.48M$13.48M$13.48M$13.48M$13.48M$13.48M
Intangibles$57.61M$59.81M$59.09M$30.42M$31.44M$31.45M$32.45M$33.45M
Total assets$253.56M$293.63M$364.98M$275.88M$83.75M$78.98M$92.95M$100.43M
Current liabilities$512.24M$501.75M$483.65M$358.95M$305.93M$275.74M$259.63M$281.54M
Short-term debt$80.81M$80.78M$83.26M$45.67M$39.87M$39.44M$34.88M$84.64M
Total liabilities$564.05M$547.71M$576.73M$455.60M$332.74M$290.46M$285.59M$311.75M
Shareholders' equity-$308.32M-$249.22M-$207.78M-$176.94M-$248.99M-$211.48M-$192.64M-$211.32M
Shares outstanding7.03M8.49M7.03M5.95M5.50M5.49M5.24M131.72M
Cash flow statement
Operating cash flow-$6.74M-$1.11M-$17.47M$8.23M$7.05M$6.01M$2.53M$5.11M
Capital expenditure——————$0$0
Free cash flow——————$2.53M$5.11M
Investing cash flow$8.45M-$9.16M$4.78M-$152,000-$153,000-$395,000-$195,000-$2.18M
Financing cash flow-$4.48M$9.14M$17.52M-$11.30M-$8.60M-$3.08M-$7.18M-$4.48M
Depreciation & amortization$800,000$2.87M$1.59M$2,000$2,000$1.00M$1.00M$4,000
Stock-based compensation$3.60M$3.63M$5.64M$3.26M$3.28M$3.31M$4.80M$3.71M

Free plan shows the latest 8 periods; Pro shows all 24 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.